Posted by Michael Wonder on 10 Jul 2026
Arialys Therapeutics announces US FDA fast track designation for ART5803, the first precision therapeutic candidate in development for the treatment of anti-NMDA receptor encephalitis
9 July 2026 - Arialys Therapeutics today announced that the US FDA has granted fast track designation to ART5803 for the treatment of anti-NMDA receptor encephalitis.
ART5803 is a novel therapeutic candidate designed using structural biology to specifically inhibit the pathogenic effects of autoantibodies that target the NMDA receptor.
